ERBB2 and breast carcinoma: The CREATE-X trial, which included patients with HER2 negative breast cancer who did not achieve pCR after neoadjuvant chemotherapy with anthracycline and/or taxane, showed that adjuvant capecitabine improved the 5-yr disease-free survival rate to 74.1% compared to 67.6% in the control group [7].